CoChat

APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease

Open access
Konijnenberg, Elles, Tijms, Betty M., Gobom, Johan, Dobricic, Valerija, Bos, Isabelle, Vos, Stephanie, Tsolaki, Magda, Verhey, Frans, Popp, Julius, Martinez-Lage, Pablo, Vandenberghe, Rik, Lleó, Alberto, Frölich, Lutz, Lovestone, Simon, Streffer, Johannes, Bertram, Lars, Blennow, Kaj, Teunissen, Charlotte E., Veerhuis, Robert, Smit, August B., Scheltens, Philip, Zetterberg, Henrik, Visser, Pieter Jelle · 2020 · Alzheimer's Research & Therapy
Cited by 50

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Background: Aggregation of amyloid β into plaques in the brain is one of the earliest pathological events in Alzheimer’s disease (AD). The exact pathophysiology leading to dementia is still uncertain, but the apolipoprotein E (APOE) ε4 genotype plays a major role. We aimed to identify the molecular pathways associated with amyloid β aggregation using cerebrospinal fluid (CSF) proteomics and to study the potential modifying effects of APOE ε4 genotype. Methods: We tested 243 proteins and protein fragments in CSF comparing 193 subjects with AD across the cognitive spectrum (65% APOE ε4 carriers, average age 75 ± 7 years) against 60 controls with normal CSF amyloid β, normal cognition, and no APOE ε4 allele (average age 75 ± 6 years). Results: One hundred twenty-nine proteins (53%) were associated with aggregated amyloid β. APOE ε4 carriers with AD showed altered concentrations of proteins involved in the complement pathway and glycolysis when cognition was normal and lower concentrations of proteins involved in synapse structure and function when cognitive impairment was moderately severe. APOE ε4 non-carriers with AD showed lower expression of proteins involved in synapse structure and function when cognition was normal and lower concentrations of proteins that were associated with complement and other inflammatory processes when cognitive impairment was mild. Repeating analyses for 114 proteins that were available in an independent EMIF-AD MBD dataset (n = 275) showed that 80% of the proteins showed group differences in a similar direction, but overall, 28% effects reached statistical significance (ranging between 6 and 87% depending on the disease stage and genotype), suggesting variable reproducibility. Conclusions: These results imply that AD pathophysiology depends on APOE genotype and that treatment for AD may need to be tailored according to APOE genotype and severity of the cognitive impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-020-00628-z

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 50

Metadata

Authors
Konijnenberg, E., Tijms, B. M., Gobom, J., Dobricic, V., Bos, I., Vos, S., Tsolaki, M., Verhey, F., Popp, J., Martinez-Lage, P., Vandenberghe, R., Lleó, A., Frölich, L., Lovestone, S., Streffer, J., Bertram, L., Blennow, K., Teunissen, C. E., Veerhuis, R., Smit, A. B., Scheltens, P., Zetterberg, H., & Visser, P. J.
Venue
Alzheimer's Research & Therapy
Published
2020-05-27
Volume
12
Issue
1
Pages
65-65
ISSN
1758-9193 (ISSN-L)
OpenAlex
W3030424674
Cited by
50
References
18
FWCI
4.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease. https://app.cochat.ai/papers/10.1186/s13195-020-00628-z
The paper
Konijnenberg, E., Tijms, B. M., Gobom, J., Dobricic, V., Bos, I., Vos, S., Tsolaki, M., Verhey, F., Popp, J., Martinez-Lage, P., Vandenberghe, R., Lleó, A., Frölich, L., Lovestone, S., Streffer, J., Bertram, L., Blennow, K., Teunissen, C. E., Veerhuis, R., . . . Visser, P. J. (2020). APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-020-00628-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.